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This scholarly review describes characteristic genetic
alterations that underlie the initiation and progression of
glioblastomas in humans and rodent models. These
alterations include the inactivation of tumor suppressor
genes such as TP53, CDKN2A/p16, RB, and PTEN and
activation of oncogenes including the epidermal growth
factor receptor (EGFR), CDK4, CDK6, Ras, and Akt.
In the first part of the review, the embryonic devel-
opment of the brain is addressed, followed by two
hypotheses on the cellular origin of gliomagenesis. With
the identification and characterization of a CNS stem cell
that persists into adulthood, the first hypothesis that
glioma represents transformation of a neural stem cell
within the subventricular zone has gained attractiveness
for brain tumor researchers. The second hypothesis is
more conventional, assuming that gliomas arise by
transformation of an intraparenchymal glial cell that
forms a mass which expands centrifugally, invading the
surrounding tissue. The therapeutic implications of neural
stem cells are also discussed, but at the moment it is not
yet clear whether this approach will prove of clinical
value.
In the next part of the review, the major pathways of
gliomagenesis such as the growth factors (EGFR,
PDGFR), components of the cell-cycle machinery (Rb,
cdk4, and the cdk inhibitor p16), and regulators of
apoptosis (p53, ARF, and PTEN) are discussed in detail
and illustrated with the aid of a series of graphics. In
addition, to determine the importance of altered path-
ways, the current mouse models of glioma formation are
described.
Next, the new and strong experimental evidence
supporting the concept of a mutator phenotype in cancer
is reviewed, including potential genes that might drive a
glioma mutator phenotype.
Finally, glioma invasiveness is discussed as a key
factor of glial malignancy from the level of growth factors
and Rac-dependent migration. Moreover, data on focal
adhesion kinase (FAK) activity and its role in the extent
and dynamics of invasiveness are given. A scheme
illustrates the link between migration and survival or
anoikis and the use of several alternating pathways in
gliomas.
Overall, this review is intellectually stimulating and
demonstrates that the mysteries of gliomagenesis are
being unraveled. However, several questions remain
whose answers will be extremely helpful in understanding
the biology of human gliomas and designing successful
therapies for them in the future.
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